Viridian Therapeutics (UK) Performance
| 0K1R Stock | 14.98 0.32 2.09% |
The entity has a beta of 0.33, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Viridian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Viridian Therapeutics is expected to be smaller as well. At this point, Viridian Therapeutics has a negative expected return of -0.38%. Please make sure to validate Viridian Therapeutics' information ratio, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if Viridian Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 102.8 M |
Viridian |
Viridian Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,972 in Viridian Therapeutics on December 26, 2024 and sell it today you would lose (474.00) from holding Viridian Therapeutics or give up 24.04% of portfolio value over 90 days. Viridian Therapeutics is generating negative expected returns and assumes 3.3996% volatility on return distribution over the 90 days horizon. Simply put, 30% of stocks are less volatile than Viridian, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Viridian Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viridian Therapeutics, and traders can use it to determine the average amount a Viridian Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1114
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 0K1R |
Estimated Market Risk
| 3.4 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viridian Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding Viridian Therapeutics to a well-diversified portfolio.
Viridian Therapeutics Fundamentals Growth
Viridian Stock prices reflect investors' perceptions of the future prospects and financial health of Viridian Therapeutics, and Viridian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viridian Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 741.51 M | ||||
| Shares Outstanding | 30.84 M | ||||
| Price To Sales | 11.50 X | ||||
| Revenue | 302 K | ||||
| EBITDA | (266.36 M) | ||||
| Total Debt | 21.09 M | ||||
| Book Value Per Share | 5.96 X | ||||
| Cash Flow From Operations | (232.32 M) | ||||
| Earnings Per Share | (5.14) X | ||||
| Total Asset | 742.4 M | ||||
| Retained Earnings | (995.86 M) | ||||
About Viridian Therapeutics Performance
Assessing Viridian Therapeutics' fundamental ratios provides investors with valuable insights into Viridian Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Viridian Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Viridian Therapeutics performance evaluation
Checking the ongoing alerts about Viridian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viridian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viridian Therapeutics generated a negative expected return over the last 90 days | |
| Viridian Therapeutics has high historical volatility and very poor performance | |
| Viridian Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (237.95 M). | |
| Viridian Therapeutics generates negative cash flow from operations | |
| Over 100.0% of the company shares are owned by institutions such as pension funds |
- Analyzing Viridian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viridian Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viridian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viridian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viridian Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viridian Therapeutics' stock. These opinions can provide insight into Viridian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.